Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023) | MicrobiomeTrials← Back to trialsNCT03998254
Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2019-06-26Est. Completion: 2028-03-31
Enrollment target: 6,000 participants Locations- Lingchuan Center for Disease Control and Prevention ( Site 0002), Guilin, Guangxi, China
- Quanzhou Center for Disease Control and Prevention ( Site 0001), Guilin, Guangxi, China
- Xiangyuan Center for Disease Control and Prevention ( Site 0003), Changzhi, Shanxi, China
- Yanhu Center for Disease Control and Prevention of Yuncheng ( Site 0004), Yuncheng, Shanxi, China
- Mianyang Center for Disease Control and Prevention ( Site 0005), Mianyang, Sichuan, China
- Santai County Center for Disease Control and Prevention ( Site 0006), Mianyang, Sichuan, China
Other microbiome trials you might be interested in
Common WartsCommon Warts (Verruca Vulgaris)Human Papilloma Virus (HPV)Warts
This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-302; referred to as COVE-3 \[C…
Overland Park, United StatesEst. completion Aug 2027
Head and Neck Squamous Cell Carcinoma (HNSCC)
A study for identification of immune determinants for response to Nivolumab in Recurrent /Metastatic HNSCC(Head and neck…
Seoul, South KoreaCompleted Mar 18, 2026
Cervical CarcinomaHuman Papillomavirus InfectionHuman Papillomavirus-Related Cervical Carcinoma
This clinical trial evaluates whether offering human papillomavirus (HPV) self-collection for cervical cancer screening …
Rochester, United StatesCompleted Sep 30, 2030